Nutrition and Metabolism Unit, Department of Pediatrics, University Children’s Hospital Queen Fabiola, Brussels, Belgium.
Orphanet J Rare Dis. 2013 Jan 11;8:8. doi: 10.1186/1750-1172-8-8.
The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.
1 型酪氨酸血症(HT1,延胡索酰乙酰乙酸酶缺乏症)的治疗管理因尼替西农的问世而发生了革命性变化,但饮食治疗仍然是必不可少的,且管理并不容易。本综述基于专家意见、已发表的病例报告和研究性研究提出了详细的管理建议,因为证据基础有限,且没有前瞻性对照研究。本文的附加价值在于详细总结了目前关于 HT1 的临床知识,并提出了管理建议。